imo-3100
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2012 (NCT01622348)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Toll-like receptor (TLR7/TLR9)INHIBITOR
Toll-like receptor (TLR7/TLR9) inhibitor
- TLR7 and TLR8INHIBITOR
TLR7 and TLR8 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- imo-3100
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01622348 | Phase 2 | May 1, 2012 | Aceragen, Inc/ |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aceragen, Inc/ | For profit | 1 | 1 | 1 | 2012 |
1 organizations
Page 1 / 1